Alaunos Therapeutics, Inc. Cash and Restricted Cash
Alaunos Therapeutics, Inc. (TCRT) had Cash and Restricted Cash of $124.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $124.00K.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $354.00K.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.39M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.94M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $124.00K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $354.00K 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $1.39M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $1.94M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $2.88M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $319.00K 10-Q · filed 2026-05-15 | |
| 2024-12-31 | $1.09M 10-Q · filed 2026-08-14 | |
| 2024-09-30 | $1.68M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $2.46M 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $4.14M 10-Q · filed 2025-05-15 | |
| 2023-12-31 | $6.06M 10-K · filed 2026-03-31 | |
| 2023-09-30 | $11.94M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $18.32M 10-Q · filed 2024-08-14 | |
| 2023-03-31 | $37.43M 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $53.00M 10-K · filed 2025-03-31 | |
| 2022-09-30 | $51.74M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $60.01M 10-Q · filed 2023-08-14 | |
| 2022-03-31 | $68.25M 10-Q · filed 2023-05-10 | |
| 2021-12-31 | $76.05M 10-K · filed 2024-04-01 | |
| 2021-09-30 | $91.72M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $76.75M 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $100.06M 10-Q · filed 2022-05-16 | |
| 2020-12-31 | $115.07M 10-K · filed 2023-03-07 | |
| 2020-09-30 | $135.47M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $153.52M 10-Q · filed 2021-08-13 | |
| 2020-03-31 | $171.00M 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $79.74M 10-K · filed 2022-03-30 | |
| 2019-09-30 | $88.42M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $43.56M 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $51.49M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $61.73M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $32.12M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $40.79M 10-Q · filed 2019-08-08 | |
| 2018-03-31 | $51.50M 10-Q · filed 2019-05-08 | |
| 2017-12-31 | $71.33M 10-K · filed 2021-03-01 | $71.33M 10-Q · filed 2018-05-10 |
| 2017-09-30 | $84.79M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $97.58M 10-Q · filed 2018-08-08 | |
| 2017-03-31 | $66.83M 10-Q · filed 2018-05-10 | |
| 2016-12-31 | $81.44M 10-K · filed 2020-03-02 | |
| 2015-12-31 | $140.72M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |